TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04223596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
Study: NCT02272465

Intervention type: OTHER
Intervention: No intervention
Description: Observational study

Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study: NCT02510066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
Study: NCT01764386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB
Description: Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLI
Description: The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual Care is a self-directed lifestyle intervention program
Study: NCT00740662

Intervention type: PROCEDURE
Intervention: Distal gastric bypass
Description: Distal gastric bypass
Study: NCT03589924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate IBBR+TiLoop®Bra
Description: Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-delayed IBBR+TiLoop®Bra
Description: Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
Study: NCT02748512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI Insert administered using the Mk II inserter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAI Insert administered using the Mk I inserter
Study: NCT01426815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
Study: NCT02990728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Study: NCT01314092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured adipose derived stem cells(low dose group)
Description: low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured adipose derived stem cells(high dose group)
Description: high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study: NCT04187911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Developmental Psychotherapy (DDP)
Description: DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual (SAU)
Description: SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites.
Study: NCT03140293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer Ethyl Chloride Spray
Description: Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
Study: NCT03244137

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: See group description.
Study: NCT01709578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02264574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
Study: NCT01709578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxychloroquine
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to the local practice.
Study: NCT03465800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed lump sum incentives
Description: delayed lump sum payments for physical activity
Study: NCT01709578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Dispensed according to the local practice.
Study: NCT02264574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
Study: NCT03405298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material
Description: Educational material is in the form of a brochure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material
Description: Educational material is in the form of a brochure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Collaborative Care
Description: Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
Study: NCT01999660

Intervention type: DEVICE
Intervention: SpaceOAR™ implantation
Study: NCT01349855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
Study: NCT01587833

Intervention type: DRUG
Intervention: Benzodiazepine (BZD) use, defined by ATC codes
Description: BZD prescription during the study period between January 1, 2001 and December 31, 2009

Intervention type: DRUG
Intervention: Benzodiazepine (BZD) use, defined by ATC codes
Description: BZD prescription during the study period between January 1, 2001 and December 31, 2009
Study: NCT02616354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem
Description: Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
Study: NCT02644538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN alfa-2a
Description: chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA \<1000copies/ml, and HBsAg\<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
Study: NCT04236713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention 1
Description: Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention 2
Description: Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
Study: NCT00641953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMX-150
Description: (0.3%) 0.5g topically BID to each foot for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMX-150
Description: (0.6%) 0.5g topically BID to each foot for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g topically BID to each foot for 4 weeks
Study: NCT03756779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Dietary intervention with dietary modification of fat intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention with dietary modification of fat intake.
Study: NCT01409226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Description: Participants undergo MRI prior to biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Participants undergo breast biopsy after 3.0-T MRI.
Study: NCT02274246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobutrol
Description: Gadobutrol administration in healthy volunteers
Study: NCT02162940

Intervention type: OTHER
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.

Intervention type: OTHER
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.

Intervention type: OTHER
Intervention: The SF 36 test
Description: The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.

Intervention type: OTHER
Intervention: The SF 36 test
Description: The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
Study: NCT01709578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulfasalazine
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leflunomide
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to the local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to the local practice.
Study: NCT04333771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study: NCT00350532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
Study: NCT00183573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 15-20 minute, motivational one-on-one counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 15-20 minute, motivational one-on-one counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 15-20 minute, motivational one-on-one counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Informational Intervention
Description: 15 minute informational DVD on safer sex

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Informational Intervention
Description: 15 minute informational DVD on safer sex

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Informational Intervention
Description: 15 minute informational DVD on safer sex
Study: NCT04333771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study: NCT04766827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
Study: NCT02640040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: llizarov external fixation device
Description: llizarov external fixation device was applied to fix the tibia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intramedullary rod fixation
Description: retrograde intramedullary rod was applied to stabilize the tibia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
Study: NCT00494065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
Study: NCT00183573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Informational Intervention
Description: 4-hour, information-only intensive group workshop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Informational Intervention
Description: 4-hour, information-only intensive group workshop
Study: NCT00494065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Spinal Manipulative Therapy + Home exercise
Description: The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
Study: NCT03052764

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injection into the bladder.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injection into the bladder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Placebo (saline) injection into the bladder.
Study: NCT00183573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Info-Motivation-Behavioral Skills Intervention
Description: 4-hour, intensive group workshop with emphasis on motivation and skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Info-Motivation-Behavioral Skills Intervention
Description: 4-hour, intensive group workshop with emphasis on motivation and skills
Study: NCT00415155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308
Description: Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.
Study: NCT02474615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDODONTIC SURGERY
Description: ENDODONTIC SURGERY

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDODONTIC SURGERY
Description: ENDODONTIC SURGERY
Study: NCT03074981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined TopClosure & Vcare Alpha
Description: Combined TopClosure \& Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks.
Study: NCT01897857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duplex Doppler ultrasonography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: duplex Doppler ultrasonography
Study: NCT05724212

Intervention type: DIAGNOSTIC_TEST
Intervention: Interferon gamma release assay (IGRA)
Description: in vitro test

Intervention type: DIAGNOSTIC_TEST
Intervention: Interferon gamma release assay (IGRA)
Description: in vitro test